Abstracts:

1. Marsh R, Brammell H, Hiatt WR, Horwitz L.  Does low dose beta blockade attenuate conditioning?  Circulation 1982;66 (Suppl II):186.*
2. Hiatt WR, Marsh R, Brammell H, Horwitz L.  The effect of aerobic conditioning on the peripheral circulation during chronic beta blockade.  Clin Res 1983;31:460A.*
3. Wolfel E, Hiatt WR, Carry M, Travis V, Brammell H, Ringel S, Horwitz L.  Beta-receptor blockade attenuates peripheral mechanisms in exercise conditioning.  Circulation 1983;68 (Suppl III):377.*
4. Hiatt WR, Wolfel E, Stoll S, Nies A, Brammell H, Horwitz L. Beta2 adrenergic blockade evaluated with epinephrine infusion in subjects receiving placebo, atenolol or nadolol.  Clin Res 1984;32:480A.*
5. Ades P, Wolfel E, Brammell H, Fee C, Barlow K, Hiatt WR, Horwitz L.  The effect of beta‑adrenergic blockade with intrinsic sympathomimetic activity (pindolol) on exercise hemodynamics.  Clin Res 1985;33:164A.*
6. Hiatt WR, Nawaz D.  Exercise performance is inversely related to the fall in ankle blood pressure post exercise in patients with peripheral vascular disease.  Clin Res 1986;34:307A.
7. Hiatt WR, Nawaz D, Brass E.  Carnitine metabolism during exercise in patients with peripheral vascular disease.  Clin Res 1987;35:107A.
8. Hiatt WR, Huang S, Regensteiner J, Micco A, Manco-Johnson M, Reeves J.  Venous occlusion plethysmography reduces arterial flow.  Clin Res 1987;35:286A.*
9. Sabichi A, Robinson WA, Hiatt WR.  WBC demargination is beta-adrenergic mediated.
10. Meier R, Sable A, Hiatt WR, Regensteiner J, Englander C.  Energy expenditure between three different types of prosthetic feet.  Arch Phys Med Rehabil 1988;69:792.*
11. Hiatt WR, Regensteiner J, Wolfel E, Ruff L and Brass E.  Carnitine metabolism during exercise: Dependence on skeletal muscle metabolic state.  FASEB J 1989;3:A941.*
12. Regensteiner J, Brass E, Hargarten M, Wolfel E and Hiatt WR.  Exercise conditioning for patients with peripheral arterial disease.  Clin Res 1989;37:288A.
13. Regensteiner JG, Hiatt WR, Byyny RL, Pickett CK and Moore LG.  Effects of estrogen and progestin on blood pressure in postmenopausal women.  Clin Res 1989;37:341A.
14. Schrier RW, Chapman AB, Hiatt WR, Johnson AM, Tschopp M, Gabow PA.  Veno­constriction may explain increased plasma atrial natriuretic peptide (ANP) and cardiac output (CO) in hypertensive autosomal dominant polycystic kidney disease (ADPKD).  Kidney Int 1990;37:251.
15. Regensteiner JG, Steiner JF, Panzer RJ and Hiatt WR.  Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease.  Clin Res 1990;38:515A. 
16. Hiatt WR, Burchfiel C, Hamman RF.  Prevalence of peripheral arterial disease in the San Luis Diabetes Study.  Clin Res 1990;38:381.*
17. Wolfel EE, Regensteiner JG, Hargarten ME, Hiatt WR.  Endurance exercise performance in patients with peripheral arterial disease (PAD).  FASEB J 1991;5:2360.*
18. Regensteiner JG, Wolfel EE, Carry MR, Ringle SP, Hargarten ME, Stamm ER, Hiatt WR. Muscle pathology associated with peripheral arterial disease (PAD).  FASEB J 1991;5:2359.*
19. Hiatt WR, Koziol B, Shapiro J, Brass EP.  Carnitine metabolism during exercise in chronic renal failure.  FASEB J 1991;5:7873.*
20. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP.  Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease (PAD).  Clin Res 1991;39:202A.*
21. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR.  Functional benefit of revascularization for patients with peripheral arterial disease.  Clin Res 1991;39:404A.
22. Hiatt WR, Brass EP.  Skeletal muscle carnitine metabolism as a marker of exercise performance in disease states.  Current Concepts in Carnitine Research Symposium 1991.*
23. England JD, Regensteiner JR, Ringle SP, Carry MR, Hiatt WR.  Muscle denervation in symptomatic peripheral arterial disease.  Muscle & Nerve 1991;14:891.*
24. Wolfel EE, Regensteiner JG, Hargarten ME, Hiatt WR.  Exercise conditioning improves endurance activity in patients with peripheral arterial disease.  FASEB J 1991;5:A776.
25. Regensteiner JG, Wolfel EE, and Hiatt WR.  Exercise training improves walking ability in patients with peripheral arterial disease.  Am J Phys Anthropol 1992;Suppl14:136.
26. Mazzotta J, Dyson LE, Falkel JE, Cerasoli PC, Hiatt WR, Regensteiner JG, Meier RH.  Effect of resistance training on strength changes in patients with peripheral arterial disease.  Phys Ther 1992;72:S30.
27. Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR.  Reduced exercise performance in non-insulin-dependent diabetes mellitus (NIDDM) is associated with impaired oxygen delivery.  FASEB J 1993;7:A518.
28. England JD, Regensteiner JR, Ferguson MD, Hiatt WR.  Evolution of neuropathy in peripheral arterial disease.  Muscle & Nerve 1993
29. Hoppel C, Hiatt W, Brass E.  Kinetics of intravenous (IV) carnitine during exercise.  FASEB J 1994, in press.
30. Hiatt W, Hoppel C, Brass E.  Effect of intravenous (IV) carnitine on muscle energy metabolism during exercise in normal subjects.  FASEB J 1994, in press.
31. Regensteiner JG, Krupski WC, Meyer T, Cranford LS, Hiatt WR.  Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial disease.  J Invest Med 1996;44:245A.
32. Brandenburg SL, Hiatt WR, Bauer TA, Reusch JEB, Vogelsong AM, Regensteiner JG.  Slowed oxygen uptake kinetic responses in women with non-insulin-dependent diabetes mellitus (NIDDM).  J Invest Med 1997;45:119A.*
33. Regensteiner JG, Bauer TA, Brandenburg SL, Sippel J, Wolfel EE, Eckel RH, Reusch JEB, Vogelsong AM, Hiatt WR.  Slowed oxygen uptake kinetic responses in women with non-insulin-dependent diabetes mellitus (NIDDM).  J Invest Med 1997;45:215A.
34. Brass EP, Hiatt WR, Hoppel CL, Bauer TA, Bhat HK.  Mitochondrial DNA injury in peripheral arterial disease.  J Invest Med 1997;45:217A.
35. Brandenburg SL, Bauer TA, Reusch JEB, Hiatt WR, Regensteiner JG.  Effect of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes mellitus. Clin Res 1998;
36. Beebe HG, Davidson MH, Chinoy DA, Herd JA, Hiatt WR, Heckman JD, Bortey EB, Forbes WP.  Cilostazol or Pentoxifylline for Claudication?  Circulation, in press.*
37. Jones DN, Nehler MR, Merli G, Durham JD, Hiatt WR, Whitehill TA, Krupski WC.  The incidence of adequate surveillance exams in a multicenter trial of deep venous thrombosis prophylaxis.  In press.  *
38. Brass EP, Hiatt WR.  Presented at Keystone Symposium ‘Mitochondrial Dysfunction in Pathogenesis’, January, 2000.
39. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, Strandness DE.  Comparison of cilostazol and pentoxifylline and the treatment of intermittent claudication.  European Society of Cardiology, August, 2000.
40. Hiatt WR.  Importance of assessing functional outcomes in the treatment of claudication.  Minerva Cardioangiologica 2000:48:98
41. Hiatt WR, Hirsch AT, Criqui MH, McDermott MM, Regensteiner JG, Walsh ME, Krook S, Comerota AJ, Creager MA, Treat-Jacobson D, Olin JW, Mohler ER III.  The PARTNERS Program:  Intensity of cardiovascular risk factor treatment and use of antiplatelet agents in patients with peripheral arterial disease (PAD) and cardiovascular disease (CVD).  Abstract:  J Am Coll Cardiol February 2001;37:278A.
42. McDermott MM, Hirsch AT, Criqui MH, Regensteiner JG, Walsh ME, Treat-Jacobson D, Krook S, Olin JW, Comerota AJ, Mohler ER III, Creager MA, Hiatt WR.  The PARTNERS Program: Knowledge base and intensity of peripheral arterial disease detection in community practice. Abstract:  J Am Coll Cardiol February 2001;37:225A-226A.
43. Hirsch AT, Hiatt WR, Criqui MH, McDermott MM, Regensteiner JG, Walsh ME, Treat-Jacobson D, Krook S, Olin JW, Comerota AJ, Mohler ER III, Creager MA.  PARTNERS: A national survey of peripheral arterial disease (PAD) symptoms and treatment intensity. Abstract:  J Am Coll Cardiol February 2001;37:226A.
44. Mohler ER, Hiatt WR, Olin J, Wade M, Jeffs R, Gerhard-Herman M, Brass EP, Hirsch AT.  Treatment of intermittent claudication with oral beraprost sodium, an orally active prostaglandin I2 analogue: A double-blind, randomized, controlled trial.  Society of Vascular Medicine and Biology,
45. Bauer TA, Hiatt WR.  Limb hemodynamics do not predict oxygen uptake kinetics during arm or leg exercise in patients with peripheral arterial disease: Evidence for skeletal muscle metabolic limitation. 
46. Mehler PS, Estacio R, Coll J, Hiatt WR. The Effect of Intensive Blood Pressure Control and Peripheral Arterial Disease. J Gen Int Med 17:2002
47. Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, Strecker PK, Anderson MW, Jones DN, Whitehill TA, Krupski WC.  Functional Outcome in a Contemporary Series of Major Lower Extremity Amputations.  Western Vascular Society 17th Annual Meeting, September 22, 2002.
48. Nehler MR, Salter KD, Esler AL, Regensteiner JG, Strecker PK, Anderson MW, Jones DN, Whitehill TA, Peyton BD, Hiatt WR.  Morbidity and Function Following Infrainguinal Bypass for Critical Limb Ischemia.  Western Vascular Society 18th Annual Meeting, September 21-24, 2003.
49. Bauer TA, Hiatt WR, Barstow TJ.  Oxygen Uptake Kinetics Following Leg Reperfusion in Peripheral Arterial Disease (PAD).  Med Sci Sports Exerc.  2003;35(5):S320.
50. Hiatt WR, Anthony RA, Koda I .  Benefit of NM-702, a Phosphodiestrerase Inhibitor, In the Treatment of Claudication.  Circulation 2003;108:IV632-633.
51. Espeland MA, Regensteiner JG, Hiatt WR, Wagenknecht LE, Bahanson J, Chiu KC, Gregg E, Haffner S, Hill J, Jaramillo SA, Knowler W. 46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council of Nutrition, Physical Activity, and Metabolism.  Phoenix AZ, 2006)

< TOP >